Skip to main content
Top
Published in: Breast Cancer Research 1/2001

01-02-2001 | Commentary

Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models

Authors: Robert L Sutherland, Elizabeth A Musgrove

Published in: Breast Cancer Research | Issue 1/2001

Login to get access

Abstract

Cyclin D1 is one of the most commonly overexpressed oncogenes in breast cancer, with 45–50% of primary ductal carcinomas overexpressing this oncoprotein. Targeted deletion of the gene encoding cyclin D1 demonstrates an essential role in normal mammary gland development while transgenic studies provide evidence that cyclin D1 is a weak oncogene in mammary epithelium. In a recent exciting development, Yu et al. demonstrate that cyclin D1-deficient mice are resistant to mammary carcinomas induced by c-neu and v-Ha-ras, but not those induced by c-myc or Wnt-1. These findings define a pivotal role for cyclin D1 in a subset of mammary cancers in mice and imply a functional role for cyclin D1 overexpression in human breast cancer.
Literature
1.
go back to reference Yu Q, Geng Y, Sicinski P: Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001, 411: 1017-1021. 10.1038/35082500.CrossRefPubMed Yu Q, Geng Y, Sicinski P: Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001, 411: 1017-1021. 10.1038/35082500.CrossRefPubMed
2.
go back to reference Motokura T, Bloom T, Kim HG, Jüppner H, Ruderman J, Kronenberg H, Arnold A: A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 1991, 350: 512-515. 10.1038/350512a0.CrossRefPubMed Motokura T, Bloom T, Kim HG, Jüppner H, Ruderman J, Kronenberg H, Arnold A: A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 1991, 350: 512-515. 10.1038/350512a0.CrossRefPubMed
3.
go back to reference Fantl V, Smith R, Brookes S, Dickson C, Peters G: Chromosome 11q13 abnormalities in human breast cancer. Cancer Surveys. 1993, 18: 77-93.PubMed Fantl V, Smith R, Brookes S, Dickson C, Peters G: Chromosome 11q13 abnormalities in human breast cancer. Cancer Surveys. 1993, 18: 77-93.PubMed
4.
5.
go back to reference Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CKW, Musgrove EA, Sutherland RL: Expression and amplification of cyclin genes in human breast cancer. Oncogene. 1993, 8: 2127-2133.PubMed Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CKW, Musgrove EA, Sutherland RL: Expression and amplification of cyclin genes in human breast cancer. Oncogene. 1993, 8: 2127-2133.PubMed
6.
go back to reference Bartkova J, Lukas J, Müller H, Lützhøft D, Strauss M, Bartek J: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer. 1994, 57: 353-361.CrossRefPubMed Bartkova J, Lukas J, Müller H, Lützhøft D, Strauss M, Bartek J: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer. 1994, 57: 353-361.CrossRefPubMed
7.
go back to reference Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994, 54: 1812-1817.PubMed Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994, 54: 1812-1817.PubMed
8.
go back to reference Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DI, Steeg PS: Overexpression of cyclin D1 mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med. 1995, 1: 1257-1260.CrossRefPubMed Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DI, Steeg PS: Overexpression of cyclin D1 mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med. 1995, 1: 1257-1260.CrossRefPubMed
9.
go back to reference Alle KM, Henshall SM, Field AS, Sutherland RL: Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clinical Cancer Res. 1998, 4: 847-854. Alle KM, Henshall SM, Field AS, Sutherland RL: Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clinical Cancer Res. 1998, 4: 847-854.
10.
go back to reference Oyama T, Kashiwabara K, Yoshimoto K, Arnold A, Koerner F: Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res. 1998, 58: 2876-2880.PubMed Oyama T, Kashiwabara K, Yoshimoto K, Arnold A, Koerner F: Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res. 1998, 58: 2876-2880.PubMed
11.
go back to reference Prall OWJ, Sarcevic B, Musgrove EA, Watts CKW, Sutherland RL: Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E–Cdk2. J Biol Chem. 1997, 272: 10882-10894. 10.1074/jbc.272.16.10882.CrossRefPubMed Prall OWJ, Sarcevic B, Musgrove EA, Watts CKW, Sutherland RL: Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E–Cdk2. J Biol Chem. 1997, 272: 10882-10894. 10.1074/jbc.272.16.10882.CrossRefPubMed
12.
go back to reference Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C: Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 1995, 9: 2364-2372.CrossRefPubMed Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C: Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 1995, 9: 2364-2372.CrossRefPubMed
13.
go back to reference Sicinski P, Liu Donaher J, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RB, Elledge SJ, Weinberg RA: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell. 1995, 82: 621-630.CrossRefPubMed Sicinski P, Liu Donaher J, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RB, Elledge SJ, Weinberg RA: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell. 1995, 82: 621-630.CrossRefPubMed
14.
go back to reference Geng Y, Yu Q, Sicinska E, Das M, Bronson RT, Sicinski P: Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. Proc Natl Acad Sci USA. 2001, 98: 194-199. 10.1073/pnas.011522998.CrossRefPubMed Geng Y, Yu Q, Sicinska E, Das M, Bronson RT, Sicinski P: Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. Proc Natl Acad Sci USA. 2001, 98: 194-199. 10.1073/pnas.011522998.CrossRefPubMed
15.
go back to reference Geng Y, Whoriskey W, Park MY, Bronson RT, Medema RH, Li T, Weinberg RA, Sicinski P: Rescue of cyclin D1 deficiency by knockin cyclin E. Cell. 1999, 97: 767-777.CrossRefPubMed Geng Y, Whoriskey W, Park MY, Bronson RT, Medema RH, Li T, Weinberg RA, Sicinski P: Rescue of cyclin D1 deficiency by knockin cyclin E. Cell. 1999, 97: 767-777.CrossRefPubMed
16.
go back to reference Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994, 369: 669-671. 10.1038/369669a0.CrossRefPubMed Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994, 369: 669-671. 10.1038/369669a0.CrossRefPubMed
17.
go back to reference Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 1988, 54: 105-115.CrossRefPubMed Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 1988, 54: 105-115.CrossRefPubMed
18.
go back to reference Sinn E, Muller WJ, Pattengale P, Tepler I, Wallace R, Leder P: Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell. 1987, 49: 465-475.CrossRefPubMed Sinn E, Muller WJ, Pattengale P, Tepler I, Wallace R, Leder P: Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell. 1987, 49: 465-475.CrossRefPubMed
19.
go back to reference D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, Cox JD, Ha SI, Belka GK, Golant A, Cardiff RD, Chodosh LA: c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med. 2001, 7: 235-239. 10.1038/84691.CrossRefPubMed D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, Cox JD, Ha SI, Belka GK, Golant A, Cardiff RD, Chodosh LA: c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med. 2001, 7: 235-239. 10.1038/84691.CrossRefPubMed
20.
go back to reference Prall OWJ, Rogan EM, Musgrove EA, Watts CKW, Sutherland RL: c-Myc or cyclin D1 mimics estrogen effects on cyclin E–Cdk2 activation and cell cycle reentry. Mol Cell Biol. 1998, 18: 4499-4508.CrossRefPubMedPubMedCentral Prall OWJ, Rogan EM, Musgrove EA, Watts CKW, Sutherland RL: c-Myc or cyclin D1 mimics estrogen effects on cyclin E–Cdk2 activation and cell cycle reentry. Mol Cell Biol. 1998, 18: 4499-4508.CrossRefPubMedPubMedCentral
21.
go back to reference Bodrug S, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM: Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994, 13: 2124-2130.PubMedPubMedCentral Bodrug S, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM: Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994, 13: 2124-2130.PubMedPubMedCentral
22.
go back to reference Rimmerman RA, Gellert-Randelman A, Diehl JA: Wnt and MEK1 cooperate to promote cyclin D1 accumulation and cellular transformation. J Biol Chem. 2000, 275: 14736-14742. 10.1074/jbc.M910241199.CrossRef Rimmerman RA, Gellert-Randelman A, Diehl JA: Wnt and MEK1 cooperate to promote cyclin D1 accumulation and cellular transformation. J Biol Chem. 2000, 275: 14736-14742. 10.1074/jbc.M910241199.CrossRef
23.
go back to reference Lin S-Y, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung M-C: β-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA. 2000, 97: 4262-4266. 10.1073/pnas.060025397.CrossRefPubMedPubMedCentral Lin S-Y, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung M-C: β-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA. 2000, 97: 4262-4266. 10.1073/pnas.060025397.CrossRefPubMedPubMedCentral
24.
go back to reference Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001, 93: 1062-1074. 10.1093/jnci/93.14.1062.CrossRefPubMed Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001, 93: 1062-1074. 10.1093/jnci/93.14.1062.CrossRefPubMed
25.
go back to reference Yu D, Hung M-C: Role of erb B2 in breast cancer chemosensitivity. BioEssays. 2000, 22: 673-680. 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.3.CO;2-1.CrossRefPubMed Yu D, Hung M-C: Role of erb B2 in breast cancer chemosensitivity. BioEssays. 2000, 22: 673-680. 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.3.CO;2-1.CrossRefPubMed
Metadata
Title
Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models
Authors
Robert L Sutherland
Elizabeth A Musgrove
Publication date
01-02-2001
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2001
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr411

Other articles of this Issue 1/2001

Breast Cancer Research 1/2001 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine